{"id":"oros-oxybutynin-or-ditropan","safety":{"commonSideEffects":[{"rate":"29-72","effect":"Dry mouth"},{"rate":"13-61","effect":"Constipation"},{"rate":"17","effect":"Dizziness"},{"rate":"14-27","effect":"Somnolence"},{"rate":"7-10","effect":"Headache"},{"rate":"8-10","effect":"Blurred vision"}]},"_chembl":{"chemblId":"CHEMBL1231","moleculeType":"Small molecule","molecularWeight":"357.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxybutynin competitively antagonizes muscarinic cholinergic receptors, particularly M3 receptors on detrusor muscle. This reduces the parasympathetic-mediated contractions of the bladder, thereby increasing functional bladder capacity and reducing urinary frequency and urgency. The OROS formulation provides extended-release delivery for improved tolerability and once-daily dosing.","oneSentence":"Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:53.672Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"},{"name":"Neurogenic detrusor overactivity in spinal cord injury patients"}]},"trialDetails":[{"nctId":"NCT00269750","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1996-07","conditions":"Urge Incontinence","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OROS® oxybutynin or Ditropan®","genericName":"OROS® oxybutynin or Ditropan®","companyName":"Alza Corporation, DE, USA","companyId":"alza-corporation-de-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency, Neurogenic detrusor overactivity in spinal cord injury patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}